Last Update20 Oct 25Fair value Increased 4.28%
Analysts have modestly increased their price target for Molina Healthcare to approximately $198, citing industry-wide optimism about core demand drivers and regulatory clarity. This comes despite concerns over margin pressure and a challenging operating environment.
Analyst Commentary
Recent Street research reflects a balanced mix of optimism and caution surrounding Molina Healthcare's outlook. Analysts are considering sector-wide dynamics, regulatory developments, and Molina's position within the managed care space when making their assessments.
Bullish Takeaways- Several bullish analysts have raised price targets on Molina Healthcare. They highlight continued strength in core demand drivers and a favorable regulatory environment, which should support long-term industry growth.
- Positive coverage notes call attention to Molina’s strong free cash flows and significant financial flexibility. This positions the company to further invest in growth and explore potential M&A opportunities.
- Expectations of extended government healthcare subsidies and enhanced regulatory clarity are seen as supportive of ongoing execution and valuation improvement.
- Some optimism is expressed regarding the company's ability to navigate a challenging environment due to its competitive positioning and agility within the managed care cohort.
- Bearish analysts caution that Molina may face several years of elevated medical loss ratio pressure as states contend with budget deficits and lingering impacts from Medicaid redeterminations. This could potentially impact margins.
- There is concern that the managed care industry is entering one of its most significant underwriting downturns in over a decade. This poses risks to near-term profitability and valuation for Molina Healthcare.
- Analysts warn of a protracted recovery in certain business lines such as Medicaid and the healthcare exchange, which may limit margin expansion and slow cyclical improvement relative to peers.
- Recent updates on Medicare Advantage Star rating criteria suggest tougher benchmarks ahead, increasing the risk of operational headwinds and competitive pressure within the plan provider landscape.
What's in the News
- U.S. judges in Texas and Connecticut ruled against legal challenges to the Medicare Drug Price Negotiation Program, supporting government efforts to control drug prices and affecting managed care providers, including Molina Healthcare (The Hill).
- Government negotiations over a potential shutdown hinge on whether to extend enhanced subsidies for Affordable Care Act health insurance. This impacts 22.4 million subsidy recipients and companies like Molina Healthcare (The Wall Street Journal).
- Molina Healthcare is facing a class action lawsuit alleging that its executives made materially false or misleading statements regarding medical cost trends and financial guidance, following two downward revisions to 2025 earnings and a significant drop in share price.
- The company reaffirmed its premium revenue guidance for 2025, projecting approximately $42 billion, and provided longer-term targets of $46 billion in 2026 and at least $52 billion in 2027.
- From April to July 2025, Molina Healthcare reported no share repurchases under its ongoing buyback program.
Valuation Changes
- Consensus Analyst Price Target: Increased moderately from $189.43 to $197.53, which reflects rising analyst optimism.
- Discount Rate: Remained unchanged at 6.78%, indicating stable perceptions of risk and required return.
- Revenue Growth: Edged up slightly from 6.80% to 6.81%, signaling a minor improvement in the top-line outlook.
- Net Profit Margin: Decreased from 2.51% to 2.37%, pointing to modestly weaker bottom-line expectations.
- Future P/E: Rose from 8.32x to 9.17x, which suggests increased valuation relative to projected earnings.
Key Takeaways
- Molina's successful RFP wins and Medicaid strategy are poised to enhance revenue, EPS growth, and net margins through efficient care coordination.
- Strategic acquisitions and disciplined medical cost management are expected to stabilize margins and boost future earnings, supporting capital deployment and growth.
- Potential Medicaid funding cuts and operational challenges may hinder Molina Healthcare's revenue growth and earnings stability amid rising medical costs and integration risks.
Catalysts
About Molina Healthcare- Provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces.
- Molina's successful track record of winning RFPs, including new contracts in Nevada and Illinois, is expected to drive significant revenue growth, with projected incremental annual premium revenue of approximately $800 million. This should positively impact revenue and EPS growth.
- The company's focus on leveraging its existing Medicaid footprint to serve high-acuity, low-income Medicare beneficiaries is working well and may enhance net margins by streamlining care coordination and administrative costs.
- Expected Medicaid rate adjustments indicate a slightly higher outcome than previously anticipated. This adjustment is likely to impact revenue favorably by aligning payments more closely with anticipated medical trends.
- Molina's acquisition pipeline, comprising many actionable opportunities, could lead to accretive additions and contribute to future earnings. Their strategy to deploy capital in acquisitions is expected to support EPS growth.
- Molina's disciplined approach to medical cost management, amidst enhancements in the rate environment, is likely to stabilize or improve net margins by mitigating the impact of rising medical costs.
Molina Healthcare Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?- Analysts are assuming Molina Healthcare's revenue will grow by 6.8% annually over the next 3 years.
- Analysts assume that profit margins will shrink from 2.7% today to 2.6% in 3 years time.
- Analysts expect earnings to reach $1.3 billion (and earnings per share of $24.06) by about September 2028, up from $1.1 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $1.1 billion.
- In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 8.4x on those 2028 earnings, down from 8.7x today. This future PE is lower than the current PE for the US Healthcare industry at 21.0x.
- Analysts expect the number of shares outstanding to decline by 5.24% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.
Molina Healthcare Future Earnings Per Share Growth
Risks
What could happen that would invalidate this narrative?- Potential Medicaid funding cuts or program changes could negatively impact Molina Healthcare's revenue and earnings trajectory.
- The implementation of new Marketplace program integrity initiatives and changes to enhanced subsidies could affect membership growth and lead to potential revenue fluctuations.
- The loss of the Virginia Medicaid contract midyear could reduce projected revenue and earnings if not offset by other membership gains.
- The moderate increase in medical costs due to high-cost drugs and behavioral health services may put pressure on net margins if rate adjustments do not adequately cover the trend.
- New acquisitions, such as ConnectiCare, running higher than target MCR initially could impact earnings if Molina is unable to effectively manage costs and achieve expected integration efficiencies.
Valuation
How have all the factors above been brought together to estimate a fair value?- The analysts have a consensus price target of $196.714 for Molina Healthcare based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $330.0, and the most bearish reporting a price target of just $153.0.
- In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $50.7 billion, earnings will come to $1.3 billion, and it would be trading on a PE ratio of 8.4x, assuming you use a discount rate of 6.8%.
- Given the current share price of $181.54, the analyst price target of $196.71 is 7.7% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
How well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
US$153
FV
25.9% overvalued intrinsic discount5.12%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$279.05
FV
31.0% undervalued intrinsic discount8.76%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
US$411.65
FV
53.2% undervalued intrinsic discount7.42%
Revenue growth p.a.
2users have liked this narrative
0users have commented on this narrative
6users have followed this narrative